Systematic review comparing LABA, olodaterol, and indacaterol: limitations

Systematic review comparing LABA, olodaterol, and indacaterol: limitations

James F Donohue Pulmonary Diseases and Critical Care Medicine, UNC School of Medicine, Chapel Hill, NC, USA Dear editor Roskell et al present a systematic review comparing the long-acting beta2 agonists (LABA), olodaterol, and indacaterol in the July edition of the Inter...

Full description

Bibliographic Details
Main Author:	Donohue JF
Format:	Article
Language:	English
Published:	Dove Medical Press 2014-12-01
Series:	International Journal of COPD
Online Access:	http://www.dovepress.com/systematic-review-comparing-laba-olodaterol-and-indacaterol-limitation-peer-reviewed-article-COPD

Similar Items

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
by: Roskell NS, et al.
Published: (2014-07-01)

Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study
by: Hsieh MJ, et al.
Published: (2022-04-01)

Indacaterol: a comprehensive review
by: Rossi A, et al.
Published: (2013-07-01)

Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses
by: Richard N. van Zyl-Smit, et al.
Published: (2023-08-01)

Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis.
by: Vincent C H Chung, et al.
Published: (2013-01-01)

Striving for optimal bronchodilation: focus on olodaterol
by: Incorvaia C, et al.
Published: (2016-03-01)

Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA
by: Cohen J, et al.
Published: (2016-04-01)

An update on the use of indacaterol in patients with COPD
by: Nadia S. Brienza, et al.
Published: (2011-02-01)

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
by: Vincken W, et al.
Published: (2014-02-01)

Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD
by: Pelaia G, et al.
Published: (2015-10-01)

Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone
by: Tamura T, et al.
Published: (2016-11-01)

Efficacy of tiotropium–olodaterol fixed-dose combination in COPD
by: Derom E, et al.
Published: (2016-12-01)

Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
by: Abdul Aziz MI, et al.
Published: (2018-10-01)

Olodaterol exerts anti-inflammatory effects on COPD airway epithelial cells
by: Nan Yang, et al.
Published: (2021-02-01)

Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity
by: Ichinose M, et al.
Published: (2018-05-01)

Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice – Results of the Non-Interventional DETECT Study
by: Plate T, et al.
Published: (2020-06-01)

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
by: Rodrigo GJ, et al.
Published: (2017-03-01)

Effectiveness of Indacaterol-Glycopyrronium in preventing COPD exacerbations in comparison to Salmeterol-Fluticasone
by: Shamim Ahmed, et al.
Published: (2022-02-01)

Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
by: Beatrix Balint, et al.
Published: (2010-09-01)

Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial
by: Dave Singh, et al.
Published: (2022-02-01)

Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study
by: Sauer R, et al.
Published: (2016-04-01)

Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol
by: Matera MG, et al.
Published: (2015-12-01)

Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study
by: Ichinose M, et al.
Published: (2018-07-01)

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study [Corrigendum]
by: Dahl R, et al.
Published: (2014-01-01)

Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population
by: Leif Bjermer, et al.
Published: (2017-12-01)

Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review
by: Ulrik CS
Published: (2014-04-01)

A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study
by: Juvelekian G, et al.
Published: (2015-10-01)

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
by: Horita N, et al.
Published: (2015-04-01)

Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol
by: Feldman GJ
Published: (2013-02-01)

Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease
by: Hataji O, et al.
Published: (2012-12-01)

Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients
by: David Miller, et al.
Published: (2020-09-01)

Interactions between glycopyrronium and indacaterol on cholinergic neurotransmission and contractile response in bovine trachealis
by: Michele Baroffio, et al.
Published: (2017-07-01)

Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
by: Ridolo E, et al.
Published: (2019-01-01)

Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China
by: Lan Y, et al.
Published: (2023-09-01)

Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease
by: Ramadan WH, et al.
Published: (2015-10-01)

Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients
by: Valipour A, et al.
Published: (2019-10-01)

Olodaterol attenuates citric acid-induced cough in naïve and ovalbumin-sensitized and challenged guinea pigs.
by: Eva Wex, et al.
Published: (2015-01-01)

A Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD
by: Andreas S, et al.
Published: (2020-08-01)

Selisih Laba Akuntansi dan Laba Kena Pajak, Manajemen Laba, Penghindaran Pajak, dan Persistensi Laba
by: , TUNGGUL AMISANI H., et al.
Published: (2014)

Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials
by: Sanjay Sethi, et al.
Published: (2020-02-01)